Cita APA

Salamero, O., Montesinos, P., Willekens, C., Pérez Simón, J. A., Pigneux, A., Récher, C., & Somervaille, T. C. (2020). First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Citación estilo Chicago

Salamero, Olga, Pau Montesinos, Christophe Willekens, José Antonio Pérez Simón, Arnaud Pigneux, Christian Récher, y Tim C.P Somervaille. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. 2020.

Cita MLA

Salamero, Olga, et al. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. 2020.